Who are GnRH Agonist (Lupron Depot)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Lupron, Micronor, cetrorelix (cetrotide), Leuprolide (GnRH agonists), Ovulation triggering with GnRH-a+rhCG, Eligard (TM).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/gnrh-agonist-lupron-depot.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

GnRH Agonist (Lupron Depot) — Competitive Intelligence Brief

GnRH Agonist (Lupron Depot) (GnRH Agonist (Lupron Depot)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: GnRH agonist. Area: Endocrinology; Oncology; Urology.

phase 3 GnRH agonist GnRH receptor Endocrinology; Oncology; Urology Small molecule Live · refreshed every 30 min

Target snapshot

GnRH Agonist (Lupron Depot) (GnRH Agonist (Lupron Depot)) — Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD). Lupron Depot is a GnRH agonist that suppresses luteinizing hormone and follicle-stimulating hormone, leading to decreased sex hormone production.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
GnRH Agonist (Lupron Depot) TARGET	GnRH Agonist (Lupron Depot)	Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	phase 3	GnRH agonist	GnRH receptor
Lupron	leuprorelin	Accord Healthcare S.L.U.	marketed	Gonadotropin Releasing Hormone Receptor Agonist	GnRH receptors	1985-01-01
Micronor	norethisterone	Johnson & Johnson	marketed	Progestin	GnRH receptors	1962-01-01
cetrorelix (cetrotide)	cetrorelix (cetrotide)	Eugonia	marketed	GnRH antagonist	GnRH receptor
Leuprolide (GnRH agonists)	Leuprolide (GnRH agonists)	University of Pisa	marketed	GnRH agonist	GnRH receptor (GNRHR)
Ovulation triggering with GnRH-a+rhCG	Ovulation triggering with GnRH-a+rhCG	Fundación Santiago Dexeus Font	marketed	Gonadotropin-releasing hormone agonist combined with recombinant human chorionic gonadotropin	GnRH receptor (for GnRH-a component); LH/hCG receptor (for rhCG component)
Eligard (TM)	Eligard (TM)	Chesapeake Urology Research Associates	marketed	GnRH agonist	GnRH receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2028-03-22 — Lupron · 9617303 · US
2031-02-05 — Lupron · 8921326 · US

Sponsor landscape (GnRH agonist class)

Takeda · 4 drugs in this class
Abbott · 3 drugs in this class
Ipsen · 3 drugs in this class
Changchun GeneScience Pharmaceutical Co., Ltd. · 3 drugs in this class
University of Pisa · 2 drugs in this class
Chong Qing Reproducive and Genetic Institute · 1 drug in this class
Chesapeake Urology Research Associates · 1 drug in this class
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) · 1 drug in this class
Enteris BioPharma Inc. · 1 drug in this class
Colorado Center for Reproductive Medicine · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). GnRH Agonist (Lupron Depot) — Competitive Intelligence Brief. https://druglandscape.com/ci/gnrh-agonist-lupron-depot. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab